Clinical Trials Browser

Phase 2/3 × Unknown × Carcinoma, Non-Small-Cell Lung × Clear all

NCT05661240 2022-12-22

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04942275 2022-09-19

PEGASUS

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04968002 2021-07-20

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04702009 2021-01-08

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03288870 2020-10-29

DOMINUS

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02416739 2020-01-27

Anticancer Activity of Nicotinamide on Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02759783 2019-08-21

CORE

Phase 2/3 Unknown

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT01407822 2018-09-11

EMERGING

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03074864 2017-03-09

TREND

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02802540 2016-08-31

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Phase 2/3 Unknown

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung

NCT02780778 2016-05-23

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02338011 2015-01-26

EGFR

Phase 2/3 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00030641 2014-01-06

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01802021 2013-03-01

QSYQT

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01481259 2012-07-03

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung